Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
10/2003
10/30/2003US20030203913 Beta3 adrenergic receptor agonists and uses thereof
10/30/2003US20030203912 Serotonergic 5HT2 agonists for treating glaucoma
10/30/2003US20030203910 A phenoxy-alkyl-quinoxalinone derivatives for inhibiting drug transport proteins that efflux therapeutic agents from cells; synergistic
10/30/2003US20030203906 Novel substituted diamine derivatives useful as motlin antagonists
10/30/2003US20030203898 Therapeutic treatment and/or prophylaxis of arteriosclerosis and hypercholesterolaemia
10/30/2003US20030203892 A synergistic therapeutic treatment for hypercholesterolemic condition
10/30/2003US20030203884 Comprises pregn-4-ene-7,21-dicarboxylic acid, 9,11-epoxy-17-hydroxy-3-oxo-, gamma-lactone, methyl ester for treatment of hypertension, cardiovascular/kidney disorders, liver diseases, and other conditions associated with salt intake
10/30/2003US20030203881 Comprises administration of tetracycline compound for treatment of Alzheimer's/Parkinson's diseases
10/30/2003US20030203870 Method and reagent for the inhibition of NOGO and NOGO receptor genes
10/30/2003US20030203864 Treatment of cancer
10/30/2003US20030203855 17-Aryl linker derivatised estrogen 3-sulphamates as inhibitors of steroid sulphatase
10/30/2003US20030203854 Composition for effecting serum cholesterol levels
10/30/2003US20030203849 Composition promoting lacrimal secretion
10/30/2003US20030203847 Methods and compositions in treating pain and painful disorders using 9949, 14230, 760, 62553, 12216, 17719, 41897, 47174, 33408, 10002, 16209, 314, 636, 27410, 33260, 619, 15985, 69112, 2158, 224, 615, 44373, 95431, 22245, 2387, 16658, 55054, 16314, 1613, 1675, 9569 or 13424 molecules
10/30/2003US20030203846 Administering to a cancer patient at least one treatment modality, containing a tyrosine kinase inhibitor and a purified heat shock protein to cure the cancer
10/30/2003US20030203484 Inducing differentiation of isolated marrow stromal cell into a neuronal cell using neuronal differentiation-inducing compound such as dimethylsulfoxide and butylated hydroxyanisole for treating nervous system disorders
10/30/2003US20030203464 Comprise Gtpase (RAC-GEF) polypeptide for treating diagnosis and treatment of cell proliferative disorders; antiproliferative agents
10/30/2003US20030203463 Nucleotide sequence which encodes a flavin monooxygenase, the corresponding protein and their uses in the spheres of diagnosis and therapy
10/30/2003US20030203452 Human chemokine beta-13
10/30/2003US20030203415 Comprises polypeptide for, diagnosis, detection and treatment of cancer
10/30/2003US20030203396 Human galactosyltransferases
10/30/2003US20030203373 Method for identifying a pharmacologically active substance
10/30/2003US20030203057 A mixture of isoflavones or isoflavone glycosides, pungent, bitter and sour substances and/or scymnol and scymnol esters; secretion of biogenic monoamines; antidepressants; seasonal affective disorder; Alzheimer's disease and much more!
10/30/2003US20030203055 Administering a selective norepinephrine norepinephrine-serotonin reuptake inhibitor, e.g., milnacipran, that is not a tricylcic antidepressant; gastrointestinal and urogenital disorders; analgesics
10/30/2003US20030203048 Oral administration to counteract dehydration resulting from vomiting, diarrhea, physical exercise or illness; especially suitable for infants, small children and the elderly; water, sodium, potassium, citrate, carbonate and structuring
10/30/2003US20030203043 Composition and method for increasing testosterone levels
10/30/2003US20030203033 Biodegradation organophosphorus polymer; administering to tumor in situ
10/30/2003US20030203030 Polymeric gel delivery system for pharmaceuticals
10/30/2003US20030203018 Stable oral pharmaceutical dosage forms
10/30/2003US20030202994 Excitatory amino acid inhibitors for treating sensitive skins
10/30/2003US20030202990 Diffusion of brain, blood barrier
10/30/2003US20030202969 Enhancing therapeutic effectiveness of nitric oxide inhalation
10/30/2003US20030202961 Methods of therapy for HIV infection
10/30/2003US20030202957 Aqueous mixture of salt and polyoxyethylene glycol; laxative
10/30/2003US20030202935 Using folinic acid; analgesics, muscle relaxants, antiinflammatory agents, psychological disorders
10/30/2003EP1496982A2 Solid forms of salts with tyrosine kinase activity
10/30/2003CA2636960A1 Pharmaceutical composition comprising a specific inhibitor of hedgehog/smoothened signaling and a corticosteroid
10/30/2003CA2484017A1 Indol-2-ones as selective inhibitors of cyclooxygenase-2
10/30/2003CA2483227A1 Antiviral inhibition of capsid proteins
10/30/2003CA2482928A1 Method of treating arrhythmias comprising administration of an a1 adenosine agonist with a beta blocker, calcium channel blocker or a cardiac glycoside
10/30/2003CA2482924A1 Adjuvant enhanced immunotherapy
10/30/2003CA2482919A1 Compositions and methods relating to endothelial cell signaling using the protease activated receptor (par1)
10/30/2003CA2482907A1 Tissue specific genes and gene clusters
10/30/2003CA2482714A1 Indane acetic acid derivatives and their use as pharmaceutical agents
10/30/2003CA2482593A1 Combination of an agent that attenuates topoisomerase 1 activity and an agent that inhibits heat shock protein 90 for use in chemotherapy
10/30/2003CA2482508A1 Combination therapy for the treatment of cancer
10/30/2003CA2482464A1 Oil body associated protein compositions and methods of use thereof for reducing the risk of cardiovascular disease
10/30/2003CA2482439A1 Use of topical compositions for the control of microbial diseases of the nail
10/30/2003CA2482035A1 Novel sodium channel blockers
10/30/2003CA2481940A1 (1-4-piperidinyl) benzimidazole derivatives useful as histamine h3 antagonists
10/30/2003CA2481934A1 Combinations of cox-2 inhibitors and other agents for the treatment of parkinson's disease
10/30/2003CA2481724A1 Screening and therapeutic methods for treating circadian rhythm disorders
10/30/2003CA2481524A1 Method of inhibiting restenosis
10/30/2003CA2481467A1 Dry powder compositions
10/30/2003CA2481120A1 Method for treating and preventing hyperparathyroidism
10/30/2003CA2481085A1 Compositions and methods for the diagnosis and treatment of tumor
10/30/2003CA2480437A1 Methods of identifying compounds that modulate a dna repair pathway and/or retroviral infectivity, the compounds, and uses thereof
10/30/2003CA2480325A1 Solid forms of salts with tyrosine kinase activity
10/30/2003CA2478991A1 Compositions and methods for augmenting kidney function
10/29/2003WO2002092081A1 Method of treatment
10/29/2003EP1357131A2 Treatment of lupus nephritis with anti-CD4OL compounds
10/29/2003EP1356820A1 DNA vaccine combined with an inducer of tumor cell apoptosis
10/29/2003EP1356815A1 Analgesic and antiinflammatory drugs
10/29/2003EP1356733A2 Pesticidal and antiparasitic compositions
10/29/2003EP1356298A2 Diagnosis and treatment of disease
10/29/2003EP1356293A2 Compositions and methods involving staphylococcus aureus protein staau-r9
10/29/2003EP1356288A1 Screening assay for cotranslational translocation interfering compounds
10/29/2003EP1356287A2 Replication assay for detecting anti-viral substances
10/29/2003EP1356284A2 Schizophrenia related genes
10/29/2003EP1356278A2 Methods and compositions for the identification and treatment of neurodegenerative disorders
10/29/2003EP1356276A2 Acetyl-coenzyme a carboxylase 2 as a target in the regulation of fat burning, fat accumulation, energy homeostasis and insulin action
10/29/2003EP1356108A2 Expression analysis of fkbp nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
10/29/2003EP1356107A2 Expression analysis of inhibitor of differentiation nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
10/29/2003EP1356097A2 The anti-neoplastic agent et-743 inhibits trans activation by sxr
10/29/2003EP1356095A2 Method for identifying metastatic tumor cells
10/29/2003EP1356092A2 Compositions and methods for the therapy and diagnosis of ovarian cancer
10/29/2003EP1356091A2 Method of detecting inflammatory lung disorders
10/29/2003EP1356085A2 Identification of modulators of dham-kinase and inflammatory diseases
10/29/2003EP1356079A2 Srebp pathway modulation through targeting hisrs
10/29/2003EP1356071A2 Genetically engineered herpes virus for the treatment of cardiovascular disease
10/29/2003EP1356058A2 Crystal structure of dimethylarginine dimethylaminohydrolase and arginine deiminase
10/29/2003EP1356053A2 Histone deacetylase inhibitors in diagnosis and treatment of thyroid neoplasms
10/29/2003EP1356046A2 Cytokine receptor zcytor19
10/29/2003EP1356042A2 Carbohydrate-associated proteins
10/29/2003EP1356041A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
10/29/2003EP1356039A2 Down syndrome critical region 1-like 1 proteins
10/29/2003EP1356036A2 Process and compositions for peptide, protein and peptidomimetic synthesis
10/29/2003EP1356032A2 Human kinases
10/29/2003EP1356028A2 Protein modification and maintenance molecules
10/29/2003EP1355943A2 Neurotransmitter transporters
10/29/2003EP1355935A2 Secreted proteins
10/29/2003EP1355923A2 Immunomodulatory peptides derived from heat shock proteins and uses thereof
10/29/2003EP1355922A2 Stress proteins and peptides and methods of use thereof
10/29/2003EP1355921A2 Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
10/29/2003EP1355916A2 Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
10/29/2003EP1355905A1 Pyrazole compounds useful as protein kinase inhibitors
10/29/2003EP1355891A2 Therapy
10/29/2003EP1355885A1 Pyridine derivatives useful as cyclooxygenase inhibitor
10/29/2003EP1355698A2 Insulin receptor activators for the treatment of metabolic disorders in humans resulting from treatment of hiv infection with hiv protease inhibitors
10/29/2003EP1355682A2 Hydrogel wound dressing and the method of making and using the same
1 ... 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 ... 1151